Literature DB >> 19692321

Reversal of docetaxel resistance with bevacizumab and thalidomide.

Yang-Min Ning1, William D Figg, William L Dahut.   

Abstract

Taxane resistance is a common clinical problem in the treatment of many metastatic malignancies. Observational clues or evidence of overcoming such resistance is important for developing treatments that can extend taxane activity. We report a case of the reversal of docetaxel resistance with the addition of antiangiogenic agents bevacizumab and thalidomide to docetaxel and prednisone in a patient with metastatic castration-resistant prostate cancer after PSAWG progression on docetaxel and prednisone. The patient then responded for an additional 7 months. The addition of bevacizumab and thalidomide after progression on docetaxel/prednisone might reverse docetaxel resistance. These or other antiangiogenic agents for overcoming clinical taxane resistance are candidates for further study.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19692321      PMCID： PMC3438454          DOI： 10.3816/CGC.2009.n.020

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


  7 in total

1.  Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.

Authors:  Giuseppe Di Lorenzo; William D Figg; Sophie D Fossa; Vincenzo Mirone; Riccardo Autorino; Nicola Longo; Ciro Imbimbo; Sisto Perdonà; Antonio Giordano; Mario Giuliano; Roberto Labianca; Sabino De Placido
Journal:  Eur Urol       Date:  2008-02-05       Impact factor: 20.096

2.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Authors:  G J Bubley; M Carducci; W Dahut; N Dawson; D Daliani; M Eisenberger; W D Figg; B Freidlin; S Halabi; G Hudes; M Hussain; R Kaplan; C Myers; W Oh; D P Petrylak; E Reed; B Roth; O Sartor; H Scher; J Simons; V Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Journal:  J Clin Oncol       Date:  1999-11       Impact factor: 44.544

3.  Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment.

Authors:  Réginald Ansiaux; Christine Baudelet; Bénédicte F Jordan; Nelson Beghein; Pierre Sonveaux; Julie De Wever; Philippe Martinive; Vincent Grégoire; Olivier Feron; Bernard Gallez
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

4.  Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?

Authors:  Jeanny B Aragon-Ching; William L Dahut
Journal:  Cancer Ther       Date:  2007

5.  Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors.

Authors:  Alastair H Kyle; Lynsey A Huxham; Devon M Yeoman; Andrew I Minchinton
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

6.  A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.

Authors:  Robert W Ross; Tomasz M Beer; Susanna Jacobus; Glenn J Bubley; Mary-Ellen Taplin; Christopher W Ryan; Jiaoti Huang; William K Oh
Journal:  Cancer       Date:  2008-02-01       Impact factor: 6.860

7.  Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.

Authors:  Paxton V Dickson; John B Hamner; Thomas L Sims; Charles H Fraga; Catherine Y C Ng; Surender Rajasekeran; Nikolaus L Hagedorn; M Beth McCarville; Clinton F Stewart; Andrew M Davidoff
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531
  7 in total
  3 in total

1.  Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.

Authors:  Robert W Ross; Matthew D Galsky; Phil Febbo; Marc Barry; Jerome P Richie; Wanling Xie; Fiona M Fennessy; Rupal S Bhatt; Julia Hayes; Toni K Choueiri; Clare M Tempany; Philip W Kantoff; Mary E Taplin; William K Oh
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

2.  Overcoming chemotherapy resistance in prostate cancer.

Authors:  Ravi A Madan; Sumanta Kumar Pal; Oliver Sartor; William L Dahut
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

3.  Versican is a potential therapeutic target in docetaxel-resistant prostate cancer.

Authors:  Naoko Arichi; Yozo Mitsui; Miho Hiraki; Sigenobu Nakamura; Takeo Hiraoka; Masahiro Sumura; Hiroshi Hirata; Yuichiro Tanaka; Rajvir Dahiya; Hiroaki Yasumoto; Hiroaki Shiina
Journal:  Oncoscience       Date:  2015-03-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.